Monday, July 18, 2011
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., is recruiting for a Phase II trial evaluating VGX-3100, its investigational SynCon DNA vaccine, in 148 subjects with high grade cervical intraepithelial neoplasia 2/3 or 3.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.